Ablative Solutions, Inc., was founded in 2011 with a vision to address the unmet need of hypertension.

Ablative Solutions’ approach targets the overactive sympathetic nervous system, which may play a role in hypertension, heart failure, kidney disease, metabolic syndrome and sleep apnea.1, 2 The Peregrine System Infusion Catheter provides physicians with a way to infuse diagnostic and therapeutic agents into the area surrounding the renal artery, where sympathetic nerves are located.

The Company is in the process of initiating two randomized sham-controlled trials using the Peregrine System Kit, which includes the Peregrine Catheter and Ablative Solutions dehydrated alcohol, for the treatment of hypertension with chemical renal denervation. These include the TARGET BP OFF-MED Clinical Trial in the EU, and the TARGET BP I Clinical Trial in the US and Europe.

Fisher et al, Central Sympathetic Overactivity: Maladies and Mechanisms, Auton Neurosci. 2009 June 15; 148(1-2): 5–15. doi:10.1016/j.autneu.2009.02.003

Schmieder et al, European Society of Hypertension Position Paper on Renal Denervation 2018, Journal of Hypertension 2018 Oct;36(10):2042-2048.